United Therapeutics (UTHR) Tops Q2 EPS by $1.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $608.49 +1.19%
Financial Fact:
Net income per basic common share (in dollars per share): 3.75
Today's EPS Names:
CIX, ARIS, COHR, More
Financial Fact:
Net income per basic common share (in dollars per share): 3.75
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- NewLake Capital Partners, Inc. (NLCP) Misses Q2 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
